Dragon Receives Approval from Shareholders in Connection with the Acquisition of Oriental Wave Holding Ltd.

Dragon Receives Approval from Shareholders in Connection with the
Acquisition of Oriental Wave Holding Ltd. 


VANCOUVER, Jan. 11  /PRNewswire-FirstCall/ -- Dragon Pharmaceutical Inc. (OTC
BB: DRUG; TSX: DDD; BBSE: DRP) ("the Company") is pleased to announce that at
the Annual Meeting of Shareholders held on January 11, 2005, the shareholders
approved the acquisition by Dragon of Oriental Wave by accepting all the
proposals in over 99% of the shares represented and voting. Over 82% of the
outstanding shares were represented at the meeting. In addition, Dr. Sun and
Dr. Wick were re-elected to the Board, and Moore Stephen Ellis Foster were
ratified to audit the Company's financial statements for the year ended
December 31, 2004.

"We, at Dragon, are delighted that this acquisition of Oriental Wave on which
we have worked hard for an extended period of time has been approved by an
overwhelming majority of our shareholders. This demonstration of unity will
provide an excellent basis to successfully face the challenges of the future,"
said Dr. Alexander Wick, President and CEO of Dragon. "Both the physical
presence of individual Dragon shareholders and the owners of Oriental Wave at
the meeting have been highly appreciated."

The Company also wishes to announce that the Toronto Stock Exchange has
conditionally approved the issue of shares in connection with the acquisition
of Oriental Wave, subject to the filing of customary documentation. The Company
and Oriental Wave expect the acquisition to close within the next couple of
days.

About Dragon Pharmaceutical Inc.

Dragon Pharmaceutical Inc. is an international bio-pharmaceutical company
headquartered in Vancouver, Canada, with a GMP production facility in Nanjing,
China. Dragon's EPO has been marketed to treat anemia due to renal failure and
surgery in 9 countries: China, India, Egypt, Brazil, Peru, Ecuador, the
Dominican Republic, Trinidad-Tobago and Kosovo. Additional regulatory
submissions are in progress throughout Central and Eastern Europe, Asia, Latin
America, the Middle East and Africa and the Company is in the final preparation
to enter the European Union market.

About Oriental Wave Holding Limited.

Oriental Wave Holding Limited is a privately held holding company of its
operating subsidiary, Shanxi Weiqida Pharmaceutical Co. Ltd. The Company
engages in production and sales of generic pharmaceutical and chemical products
with 3 production facilities in Datong city, China.

  For further information please contact:
  Dragon Pharmaceutical Inc.
  Garry Wong, CFA, IMBA
  Telephone: [phone] or North America Toll Free: 1-877-388-3784
  Email: 
  Website: http://www.dragonbiotech.com/ or http://www.dragonpharma.com/
  or
  Renmark Financial Communications Inc.
  John Boidman : 
  Sylvain Laberge : 
  Media - Cynthia Lane : 
  Telephone: [phone]
  Website: http://www.renmarkfinancial.com/

DATASOURCE: Dragon Pharmaceuticals Inc.



CONTACT: Dragon Pharmaceutical Inc., Garry Wong, CFA, IMBA, Telephone:

[phone] or North America Toll Free: 1-877-388-3784, Email:

, Website: http://www.dragonbiotech.com/ or

http://www.dragonpharma.com/; or Renmark Financial Communications Inc., John
Boidman:

, Sylvain Laberge:

, Media - Cynthia Lane:

, Telephone: [phone], Website:

http://www.renmarkfinancial.com/

Copyright